Literature DB >> 31882490

Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.

Kiyoshi Maeda1,2, Masatsune Shibutani2, Akiko Tachimori3, Takafumi Nishii3, Naoki Aomatsu3, Tatsunari Fukuoka2, Hisashi Nagahara2, Hiroshi Otani2, Toru Inoue3, Masaichi Ohira3.   

Abstract

BACKGROUND/AIM: Neoadjuvant chemoradiotherapy (CRT) is a standard treatment for patients with clinical Stage II/III rectal cancer. However, the benefit of postoperative adjuvant chemotherapy for patients after neoadjuvant CRT is uncertain. Recently, neoadjuvant rectal (NAR) score was suggested as an independent prognostic factor for patients with rectal cancer after neoadjuvant CRT. The aim of this study was to examine the prognostic significance of NAR score in rectal cancer patients who underwent neoadjuvant CRT followed by surgery, and to investigate which patients may benefit from postoperative adjuvant therapy. PATIENTS AND METHODS: A total of 72 patients who underwent neoadjuvant CRT followed by R0 resection for clinical stage II /III rectal cancer were evaluated. The correlation between NAR score, various clinicopathological factors and disease recurrence were evaluated.
RESULTS: Disease recurrence was significantly more often observed in patients with incomplete neoadjuvant CRT, tumor regression grade (TRG) 3-4, and high NAR score. Multivariate analysis revealed that NAR score was an independent predictor of disease recurrence.
CONCLUSION: NAR score may be one of the predictive markers for disease recurrence in patients who underwent neoadjuvant CRT followed by surgery for rectal cancer. Patients with a low NAR score may benefit form postoperative adjuvant chemotherapy. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Rectal cancer; adjuvant therapy; chemoradiotherapy; neoadjuvant rectal score

Mesh:

Year:  2020        PMID: 31882490      PMCID: PMC6984106          DOI: 10.21873/invivo.11772

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  29 in total

1.  Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?

Authors:  Ravi P Kiran; Hasan T Kirat; Adele N Burgess; Pasha J Nisar; Matthew F Kalady; Ian C Lavery
Journal:  Ann Surg Oncol       Date:  2011-09-21       Impact factor: 5.344

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Should we consider adjuvant therapy for rectal cancer after neoadjuvant chemoradiotherapy?

Authors:  Al B Benson
Journal:  Clin Adv Hematol Oncol       Date:  2016-10

4.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

5.  No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT).

Authors:  Aldo Sainato; Valentina Cernusco Luna Nunzia; Vincenzo Valentini; Antonino De Paoli; Enrici Riccardo Maurizi; Marco Lupattelli; Cynthia Aristei; Cristiana Vidali; Monica Conti; Alessandra Galardi; Pietro Ponticelli; Maria Luisa Friso; Tiziana Iannone; Falchetto Mattia Osti; Bruno Manfredi; Marianna Coppola; Cinzia Orlandini; Luca Cionini
Journal:  Radiother Oncol       Date:  2014-11-14       Impact factor: 6.280

6.  Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

Authors:  Katherine L Kahn; John L Adams; Jane C Weeks; Elizabeth A Chrischilles; Deborah Schrag; John Z Ayanian; Catarina I Kiefe; Patricia A Ganz; Nirmala Bhoopalam; Arnold L Potosky; David P Harrington; Robert H Fletcher
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 7.  Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.

Authors:  K Bujko; B Glimelius; V Valentini; W Michalski; M Spalek
Journal:  Eur J Surg Oncol       Date:  2015-04-13       Impact factor: 4.424

8.  Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection.

Authors:  Fahima Dossa; Sergio A Acuna; Aaron S Rickles; Mariana Berho; Steven D Wexner; Fayez A Quereshy; Nancy N Baxter; Sami A Chadi
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

9.  Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Wen-Hua Fan; Jian Xiao; Xin An; Wu Jiang; Li-Ren Li; Yuan-Hong Gao; Gong Chen; Ling-Heng Kong; Jun-Zhong Lin; Jian-Ping Wang; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-06       Impact factor: 4.553

10.  Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients.

Authors:  Xiang Hu; Ya-Qi Li; Xiao-Ji Ma; Long Zhang; San-Jun Cai; Jun-Jie Peng
Journal:  Cancer Cell Int       Date:  2019-05-14       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.